Avalo Therapeutics, Inc.
- Open
- 18.43
- Day high
- 18.99
- Day low
- 17.73
- Prev close
- 18.48
- Volume
- 529K
- Mkt cap
- $940M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 13.8
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$5.9M over the last 3 months (0 open-market buys, 29 sales)
- 🏛Institutions accumulating (13F)
Avalo Therapeutics, Inc. (AVTX) is a Healthcare company listed on NASDAQ. The stock is up 282% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 29 sales (SEC Form 4).
Avalo Therapeutics, Inc. (AVTX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 9 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AVTX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-1.00 | $-0.98 | +2.0% | — | — |
| Mar 23, 2026 | $-1.54 | $-0.37 | +76.0% | $59000 | +0.0% |
| Nov 6, 2025 | $-1.67 | $-2.19 | -31.1% | — | — |
| Aug 7, 2025 | $-1.43 | $-1.92 | -34.3% | — | — |
| Mar 20, 2025 | $-0.39 | $-7.95 | -1938.5% | $192000 | — |
| Nov 7, 2024 | $-1.19 | $-2.83 | -137.8% | $249000 | — |
| Mar 29, 2024 | $-4.80 | $-116.21 | -2321.0% | $571000 | +90.3% |
| Nov 9, 2023 | $-261.90 | $-26.19 | +90.0% | $236000 | -21.3% |
| Aug 3, 2023 | $-214.29 | $-140.48 | +34.4% | $643000 | +28.6% |
| May 4, 2023 | $-230.95 | $-202.38 | +12.4% | $475000 | -52.5% |
| Aug 4, 2022 | $-428.57 | $-328.57 | +23.3% | $1M | -12.9% |
| May 5, 2022 | $-400.16 | $-571.66 | -42.9% | $1M | +81.7% |
AVTX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 25, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 1,450 | $18.00 |
| Jun 25, 2026 | Philip Ron Mdirector | Grant | 40,200 | $17.83 |
| Jun 25, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 1,450 | $8.04 |
| Jun 12, 2026 | Doyle Mittieofficer: Chief Medical Officer | Tax | 1,084 | $13.10 |
| Jun 12, 2026 | Riley Jenniferofficer: Chief Strategy Officer | Tax | 588 | $13.10 |
| Jun 12, 2026 | VARKI PAULofficer: Chief Legal Officer | Tax | 1,081 | $13.10 |
| Jun 12, 2026 | Sullivan Christopher Ryanofficer: Chief Financial Officer | Tax | 138 | $13.10 |
| Jun 4, 2026 | Lind Kevin Robertdirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | KANTOFF AARONdirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Truex Samanthadirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Heffernan Michael Thomasdirector | Grant | 29,500 | $13.96 |
| Jun 4, 2026 | KAPLAN GILLAdirector | Grant | 20,100 | $13.96 |
| Jun 4, 2026 | Jain Ritadirector | Grant | 20,100 | $13.96 |
| Jun 1, 2026 | Doyle Mittieofficer: Chief Medical Officer | Option | 679 | $8.04 |
| Jun 1, 2026 | Doyle Mittieofficer: Chief Medical Officer | Sell | 679 | $16.00 |
Source: AVTX SEC Form 4 filings, latest Jun 25, 2026. For informational purposes only — not investment advice.
See the full AVTX insider & 13F page →Avalo Therapeutics, Inc. company profile
Overview
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a clinical-stage precision medicine company founded in 2011 and headquartered in Rockville, Maryland. Originally incorporated as Cerecor Inc., the company rebranded to Avalo Therapeutics in August 2021 to better reflect its focus on developing targeted therapeutics. The company went public in October 2015 and has since evolved into a biotechnology firm specializing in treatments for immunology, immuno-oncology, and rare genetic diseases where significant unmet medical needs exist.
Business
Avalo Therapeutics operates in the biotechnology sector, specifically focusing on precision medicine - an approach that tailors medical treatment to individual characteristics of patients and their diseases. The company develops targeted therapeutic drugs that are designed to work more effectively for specific patient populations based on genetic, biomarker, or other molecular characteristics. The company's pipeline consists of several monoclonal antibodies and substrate replacement therapies across three main therapeutic areas: Immunology and Inflammatory Diseases: The flagship product is AVTX-002, a fully human anti-LIGHT monoclonal antibody. LIGHT is a protein that plays a crucial role in inflammatory processes throughout the body. This drug is currently in Phase II clinical trials for non-eosinophilic asthma (a type of asthma not driven by eosinophil immune cells) and inflammatory bowel diseases including Crohn's disease and ulcerative colitis. The company also completed Phase III trials for COVID-19 acute respiratory distress syndrome. Additionally, AVTX-007 is a fully human anti-IL-18 monoclonal antibody in Phase I trials for Still's disease, a rare inflammatory condition. Rare Genetic Diseases: The company develops substrate replacement therapies for ultra-rare genetic disorders called congenital disorders of glycosylation (CDGs). These are inherited diseases where the body cannot properly attach sugar molecules to proteins, leading to severe developmental and health problems. AVTX-801 provides D-galactose substrate replacement for PGM1 deficiency, while AVTX-803 provides L-fucose substrate replacement for LADII deficiency. Both are in Phase III clinical trials. Revenue generation is currently minimal, with the company reporting only $441,000 in total revenue for 2024, likely from research collaborations or licensing agreements. The company is pre-commercialization and focused entirely on clinical development.
Revenue model
As a clinical-stage biotechnology company, Avalo Therapeutics does not yet generate meaningful revenue from product sales. The company's current business model is based on research and development funding through a combination of equity financing, potential government grants, and strategic partnerships. The minimal revenue reported ($441,000 in 2024) likely comes from research collaboration agreements or milestone payments from potential partners. The company's future revenue model will depend on successfully advancing its drug candidates through clinical trials and ultimately achieving regulatory approval. Once approved, revenue would come from pharmaceutical product sales either directly or through licensing agreements with larger pharmaceutical companies. Given the focus on rare diseases, the company may be eligible for premium pricing through orphan drug designations, which provide market exclusivity and other incentives for treating rare conditions affecting fewer than 200,000 patients in the United States. Key factors that could impact the company's financial performance include clinical trial success rates, regulatory approval timelines, competition from other biotechnology companies developing similar treatments, and the company's ability to secure additional funding to sustain operations through the lengthy drug development process. The biotechnology industry is characterized by high development costs, long timelines (often 10+ years from discovery to market), and significant regulatory risk, but successful drugs can generate substantial returns. Manufacturing costs, intellectual property protection, and market access negotiations with healthcare payers will also influence future profitability margins.
Competitive moat
Avalo Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this stage of development. The company's potential moat primarily rests on intellectual property protection around its specific monoclonal antibody designs and formulations, as well as any proprietary manufacturing processes or delivery mechanisms. In the rare disease space, the company may benefit from orphan drug exclusivity, which provides seven years of market exclusivity in the United States for approved treatments of rare diseases. This regulatory protection can create a temporary moat against direct competition. Additionally, the company's focus on precision medicine approaches targeting specific patient populations could provide some differentiation if biomarker-driven patient selection proves superior to broader treatment approaches. However, the company faces significant competitive threats. Large pharmaceutical companies with substantially greater resources are actively developing treatments in similar therapeutic areas. The anti-inflammatory and immunology space is particularly crowded, with established players like AbbVie, Johnson & Johnson, and Roche having approved products and extensive pipelines. In rare genetic diseases, while the patient populations are smaller, other biotechnology companies are pursuing similar substrate replacement therapy approaches. The company's competitive position is further weakened by its limited financial resources compared to larger competitors, its early-stage clinical development status, and the inherent risks of drug development failure. Without approved products generating revenue, the company lacks the cash flow advantages that would allow for sustained competitive investment in research and development. The moat is therefore quite narrow and largely dependent on successful clinical execution and regulatory approval.
Risks & safety
The margin of safety appears relatively strong from a liquidity perspective but concerning from an operational standpoint. **Liquidity and Solvency:** - Cash position of $125 million as of Q1 2025 provides substantial near-term runway - Current ratio of 22.6 indicates excellent short-term liquidity - Minimal debt with debt-to-equity ratio near zero - Current cash burn rate of approximately $49 million annually suggests roughly 2.5 years of operating runway **Valuation Metrics:** - Price-to-book ratio of 0.69 suggests trading below book value - Graham net-net working capital value significantly above current market price - Enterprise value appears reasonable relative to cash position **Other Considerations:** - No revenue generation creates complete dependence on clinical trial success - Biotech sector inherently carries high binary risk from regulatory outcomes - Small market capitalization of $44 million increases volatility risk - Limited diversification with concentrated pipeline creates concentration risk
Recent development
Based on the available financial data, Avalo Therapeutics has undergone significant strategic evolution over recent years. The company's name change from Cerecor Inc. to Avalo Therapeutics in August 2021 marked a strategic pivot toward precision medicine and targeted therapeutics. The company has been advancing multiple clinical programs simultaneously, with AVTX-002 progressing through Phase II trials for inflammatory conditions and completing Phase III trials for COVID-19 applications. The development of AVTX-007 for Still's disease represents expansion into additional inflammatory conditions, while the rare disease portfolio with AVTX-801 and AVTX-803 has advanced to Phase III trials. Financially, the company appears to have strengthened its balance sheet significantly, with cash and short-term investments increasing from approximately $7.4 million at the end of 2023 to $134.5 million by the end of 2024. This dramatic improvement in cash position suggests successful equity financing rounds, likely enabling the company to fund its clinical development programs through key milestones. The company has maintained a focused approach on precision medicine, developing treatments for specific patient populations with high unmet medical needs rather than pursuing broader market opportunities. This strategy aligns with current trends in biotechnology toward personalized medicine and targeted therapies, particularly in rare disease applications where smaller patient populations can still support viable commercial opportunities.
AVTX company profile · for informational purposes only — not investment advice.
Track AVTX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free